The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA.
 
Thomas Decker
Consulting or Advisory Role - iOMEDICO; Novartis
Speakers' Bureau - iOMEDICO; Novartis
 
Cosima Brucker
Honoraria - Intuitive Surgical
Research Funding - Eisai; Novartis; Roche
Travel, Accommodations, Expenses - CMR Surgical; Medtronic
 
Anne Engel
No Relationships to Disclose
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Roche
 
Thomas Göhler
No Relationships to Disclose
 
Christian Jackisch
Honoraria - AstraZeneca; Exact Sciences; Gilead Sciences; Lilly; Novartis; Pfizer; Pierre Fabre; Roche Pharma AG; Sanofi Aventis GmbH
Consulting or Advisory Role - AstraZeneca; Genomic Health; Genomic Health; Novartis; Roche; Seagen; Tesaro
Research Funding - Genomic Health (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis; Roche
 
Jan Janssen
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ipsen; Johnson & Johnson; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ipsen; Johnson & Johnson; Novartis; Pfizer; Roche
 
Andreas Köhler
Consulting or Advisory Role - Amgen; Daiichi Sankyo Pharmaceutical; MSD; Novartis; Pfizer; Roche
Research Funding - GBG Forschungs
Travel, Accommodations, Expenses - Stada
 
Kerstin Luedtke-Heckenkamp
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Novartis; Pfizer; Roche Pharma AG; Seagen
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Novartis; Roche Pharma AG; Seagen
Research Funding - Daiichi Sankyo/Astra Zeneca (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Celgene/Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Novartis; Pfizer; Roche Pharma AG
 
Diana Lüftner
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo Pharmaceutical; GlaxoSmithKline; L'Oreal; Lilly O.; Novartis
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo Pharmaceutical; GlaxoSmithKline; L'Oreal; Lilly O.; Novartis
Speakers' Bureau - Amgen; AstraZeneca; Daiichi Sankyo Pharmaceutical; GlaxoSmithKline; L'Oreal; Lilly O.; Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Daiichi Sankyo Pharmaceutical; GlaxoSmithKline; L'Oreal; Lilly O.; Novartis
 
Marion van Mackelenbergh
Honoraria - Amgen; AstraZeneca/Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Lilly; Mylan; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Amgen; AstraZeneca/Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Lilly; Molecular Health; Mylan; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH; Gilead Sciences; Lilly
 
Frederik Marmé
Honoraria - AGENDIA; Amgen; AstraZeneca; Clovis Oncology; Daiichi Sankyo; Eisai; Genomic Health; Gilead Sciences; GlaxoSmithKline; Immunomedics (Inst); Lilly; MSD Oncology; Myriad Genetics; Novartis; Pfizer; PharmaMar; Pierre Fabre; Roche/Genentech; Seagen
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); Clovis Oncology; CureVac; Eisai; Genomic Health; Gilead Sciences; GlaxoSmithKline; Immunomedics (Inst); Pfizer; Roche (Inst); Seagen; Seagen; Vaccibody (Inst)
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Tesaro (Inst); Vaccibody (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Pfizer; Roche
 
Arnd Nusch
Research Funding - AstraZeneca; Novartis; Roche
 
Beate Rautenberg
Honoraria - Amgen; Clovis Oncology; Daiichi Sankyo Pharmaceutical; Lilly O.; MSD; Roche; WPO
Consulting or Advisory Role - Lilly O.; MSD; Roche
Research Funding - Daiichi Sankyo Pharmaceutical; Lilly O. (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo Pharmaceutical; Lilly O.; Roche
 
Toralf Reimer
Honoraria - Novartis
 
Marcus Schmidt
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; SeaGen
Consulting or Advisory Role - AstraZeneca; BioNTech; Daiichi Sankyo/Astra Zeneca; Eisai; Lilly; MSD Oncology; Novartis; Pantarhei Bioscience; Pfizer; Pierre Fabre; Roche; SeaGen
Research Funding - AstraZeneca (Inst); BioNTech (Inst); Genentech/Roche (Inst); Novartis (Inst); Pantarhei Bioscience (Inst); Pfizer (Inst); Roche (Inst); SeaGen (Inst)
Patents, Royalties, Other Intellectual Property - EP 2390370 B1 A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent; EP 2951317 B1 METHOD FOR PREDICTING THE BENEFIT FROM INCLUSION OF TAXANE IN A CHEMOTHERAPY REGIMEN IN PATIENTS WITH BREAST CANCER
 
Rudolf Weide
Research Funding - Amgen (Inst); Biotest (Inst); Bristol-Myers Squibb (Inst); CSL Behring (Inst); Daiichi Sankyo Pharmaceutical (Inst); Eisai (Inst)
 
Pauline Wimberger
Honoraria - Amgen; AstraZeneca; Clovis Oncology GmbH; Eisai; GlaxoSmithKline; Lilly; MSD Oncology; Novartis/Pfizer; Pfizer; Roche Pharma AG; Teva
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology GmbH; Eisai Germany; Eisai Germany; GlaxoSmithKline; Lilly; MSD Oncology; Novartis; Pfizer; PharmaMar; Roche Pharma AG; Tesaro; Teva
Travel, Accommodations, Expenses - Roche Pharma AG
 
Christian Roos
Employment - Novartis
 
Achim Wöckel
Consulting or Advisory Role - Amgen; AstraZeneca; Aurikamed; Celgene; Eisai; Lilly O.; Novartis